MUC1 and neoplasm: To develop an immunotherapeutic approach for breast cancer, we chose to target an aberrantly glycosylated form of MUC1, which represents a cancer-expressed neoantigen that can be selectively targeted by antibodies and CARs, thereby alleviating concerns associated with “on target off tumor” toxicities [43].